Epilepsy (Adults): Disease Analysis Report and Forecast

This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035.

GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%.

In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the 7MM, driven by high branded prices, a wider array of branded options, and the largest diagnosed prevalent population among the seven markets. The 5EU contributed approximately $1.8 billion, accounting for 15.8% of the total market, with Germany and the UK the largest individual contributors. Japan contributed approximately $429.4 million, representing 3.8% of the total market. By 2035, the US share is expected to rise further to 82.9% of global sales, while Japan's share is expected to fall to 2.8%, reflecting its markedly slower growth trajectory and fewer drug launches.

Scope

• Overview of epilepsy, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized epilepsy market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2025 to 2035.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global epilepsy market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM epilepsy therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM epilepsy therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.